Roche’s (ROG: SIX) immuno-oncology drug Tecentriq (atezolizumab) continues its charge in lung cancer with another approval in the USA.
The US Food and Drug Administration (FDA) has approved Tecentriq as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression or PD-L1 stained tumor-infiltrating covering at least 10% of the tumor area, as determined by an FDA-approved test, with no EGFR or ALK genomic tumour aberrations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze